Osteokare, a key division of Medley Pharmaceuticals, has been a trusted name in the pain and analgesic segment for over a decade. Focused on the management of acute and chronic pain, the division offers a wide portfolio of therapies including NSAIDs, opioids, and adjuvant medications, built on innovation, scientific expertise, and patient-centered care.
Pain whether acute or chronic significantly affects comfort, mobility, and overall quality of life. The Osteokare division addresses a broad spectrum of conditions including:
With a focus on restoring function and relieving suffering, Osteokare therapies support patients across all age groups.
At the heart of Osteokare’s success is its flagship brand:
A market leader in the Nortriptyline + Pregabalin + Methylcobalamin segment, Nortipan M is the first triple combination in India to offer sustained release pregabalin alongside nortriptyline and methylcobalamin. It is a trusted option in the treatment of:
This unique formulation delivers superior symptom relief, sets a new therapeutic benchmark, and has earned Nortipan M the No. 1 position in its segment.
Clinically aligned with modern treatment protocols
Developed to maximize therapeutic benefit while minimizing adverse effects
Manufactured in WHO-GMP certified facilities with stringent quality control
Affordable and accessible, helping expand care across urban and rural India
Company Identification Number
( CIN ) : U24230MH1975PLC018296
Medley House, D2,
M.I.D.C. Area,
Andheri (East),
Mumbai-400 093, INDIA
